Sagimet Biosciences Announced A License Agreement With A Subsidiary Of Teva Pharmaceutical

Benzinga·12/17/2025 12:06:43

语音播报

License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applications
Collaboration supports Sagimet's fixed-dose combination (FDC) program currently in clinical development
Sagimet's Phase 1 pharmacokinetic (PK) trial of combination of denifanstat and resmetirom is underway with topline data anticipated by the end of 2025
Sagimet anticipates selecting one of the innovative forms of resmetirom licensed from TAPI for combination with denifanstat in a fixed dose combination (FDC) tablet for use in Phase 3